Status:
COMPLETED
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Head and Neck Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This randomized, open-label, phase III study will be performed in patients with recurrent and/or metastatic head and neck cancer which has progressed after platinum-based therapy. The objectives of th...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, which has recurred/metastasised and is not amenable for salvage surgery or radiotherapy.
- Documented progressive disease based on investigator assessment according to RECIST, following receipt of a cisplatin and/or carboplatin and/or Nedaplatin based regimen administered for recurrent and/or metastatic disease independent of whether patient progressed during or after platinum based therapy.
- Measurable disease according to RECIST (version 1.1).
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at Visit 2.
- Male and female patients age is 18 years or older
- Signed and dated written informed consent that is in compliance with ICH-GCP and local law.
- Exclusion criteria:
- Progressive disease within three months after completion of curatively intended treatment for locoregionally advanced or for metastatic head and neck squamous cell cancer (HNSCC).
- Primary tumour site nasopharynx (of any histology), sinuses, and/or salivary glands.
- Any other than one previous platinum based systemic regimen given for recurrent and/or metastatic disease, with the exception of immunotherapy used either before or after platinum based treatment. Re-challenge with the platinum based regimen after a temporary break is considered an additional line regimen only in case of progression within the break.
- Prior treatment with EGFR-targeted small molecules.
- Treatment with any investigational drug less than four weeks or anti-cancer therapy less than three weeks prior to randomization (except palliative radiotherapy to bones to alleviate pain).
- Unresolved chronic toxicity, other than hearing loss, tinnitus or dry mouth, CTCAE grade \>2 from previous anti-cancer therapy or unresolved skin toxicities CTCAE grade \>1 and/or diarrhoea CTCAE grade \>1 caused by prior treatment with EGFR targeted antibodies.
- Previous tumour bleeding CTCAE grade =3.
- Requirement for treatment with any of the prohibited concomitant medications.
- Major surgical or planned procedure less than four weeks prior to randomization (isolated biopsies are not considered as major surgical procedures).
- Any other malignancy unless free of disease for at least five years except for:
- Other HNSCC of a location as described in inclusion criterion number 1
- Appropriately treated superficial basal cell skin cancer
- Surgically cured cervical cancer in situ
- For Korea: endoscopically cured superficial esophageal and/or gastric cancer is allowed
- Known lesion or signs of brain metastasis.
- Known pre-existing interstitial lung disease (ILD).
- Clinically relevant cardiovascular abnormalities, as judged by the investigator, such as, but not limited to, uncontrolled hypertension, congestive heart failure NYHA classification =III, unstable angina, myocardial infarction within six months prior to randomization, or poorly controlled arrhythmia.
- Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom in the opinion of the investigator, e.g. Crohn's disease, malabsorption or CTCAE grade \>1 diarrhoea of any aetiology at randomization.
- Known HIV, active hepatitis B, active hepatitis C, and/or other known severe infections, including but not limited to tuberculosis, as judged by the investigator.
- Other significant disease that in the investigator's opinion would exclude the subject from the trial.
- Screening laboratory values:
- Absolute neutrophil count (ANC) \<1.5x10\^9/l
- Platelet count \<75x10\^9/l
- Total bilirubin \>1.5 times the upper limit of normal (ULN)
- Aspartate amino transferase (AST) or alanine amino transferase (ALT) \>3 times the ULN (if related to liver metastases \>5 times the ULN)
- Calculated creatinine clearance \<50 ml/min (as evidenced by using the Cockcroft-Gault formula).
- Women of child-bearing potential and men who are able to father a child, unwilling to be abstinent or to use adequate contraception during the trial and for at least six months after end of treatment. Adequate methods of contraception and definition of child-bearing potential.
- Pregnancy or breast feeding.
- Known or suspected hypersensitivity to any of the study medications or their excipients.
- Patients unable to comply with the protocol, in the opinion of the investigator.
Exclusion
Key Trial Info
Start Date :
June 7 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 2 2024
Estimated Enrollment :
340 Patients enrolled
Trial Details
Trial ID
NCT01856478
Start Date
June 7 2013
End Date
October 2 2024
Last Update
February 14 2025
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Chao-Yang Hospital
Beijing, China, 100020
2
Cancer Hospital of Chinese Academy of Medical Science
Beijing, China, 100021
3
Navy General Hospital
Beijing, China, 100037
4
Peking Union Medical College Hospital
Beijing, China, 100730